Healthcare · Biotechnology · NASDAQ
| Market cap | $29.33B |
|---|---|
| Trailing P/E | 27.5 |
| FCF yield | 1.6% |
| Revenue growth (YoY) | +65.2% |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | — |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
Alnylam Pharmaceuticals, Inc. trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Jefferson Shreve | House | Sell | $15,001 - $50,000 | May 15, 2025 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Feb 7, 2024 |
| Daniel Goldman | House | Buy | $15,001 - $50,000 | Apr 3, 2023 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Dec 8, 2020 |
| Barbara J Honorable Comstock | House | Sell | $15,001 - $50,000 | Mar 5, 2018 |
| Barbara J Honorable Comstock | House | Buy | $15,001 - $50,000 | Oct 12, 2017 |
| Richard L. Hanna | House | Buy | $50,001 - $100,000 | Jan 6, 2017 |
| Richard L. Hanna | House | Sell | $100,001 - $250,000 | Jan 6, 2017 |
| Richard L. Hanna | House | Buy | $100,001 - $250,000 | Nov 25, 2016 |